Our findings expand the opportunity to treat patients who have overweight or obesity and existing heart disease without Type 1 or Type 2 diabetes, and we have a chance to significantly reduce their risk of a secondary cardiovascular event including death. Among the study limitations were including adults with prior cardiovascular disease, thereby not investigating primary prevention of cardiovascular disease (people with no history of a heart attack, stroke and/or peripheral artery disease)
If youre interested in weight loss treatment now, we offer FDA-approved options like semaglutide and tirzepatide
The cardiovascular protection begins shortly after starting treatment and persists long-term
123 Vps34 lactylation at K356 and K781 enhances its interaction with Beclin1, Atg14L, and UVRAG and then increases Vps34 lipid kinase activity, thereby promoting autophagic flux and endolysosomal trafficking
Many large outlets run affiliate programs, which means they earn a commission if someone clicks through their site and signs up
Pennsylvania (Independence Blue Cross) : As of January 1, 2025, IBX restricted Wegovy and Ozempic coverage to FDA-approved conditions (diabetes, heart disease), barring coverage for obesity or weightloss only